fox files

Kazakhstan, South Korea Engineer Live Bird Flu–Tuberculosis Franken-Virus: Journal ‘Veterinary World’

The discovery coincides with a U.S. policy move placing bird flu and bovine tuberculosis under indefinite emergency status—raising urgent questions of intent and global coordination.

A new study published last month in Veterinary World confirms that scientists from Kazakhstan and South Korea have engineered a live hybrid virus that combines genetic material from avian influenza “bird flu” and Mycobacterium bovis, the bacterium that causes bovine tuberculosis.

Governments all over the world are quietly generating an army of new bird flu pathogens, without a peep from the mainstream media or popular influencers.

The new chimeric influenza–tuberculosis pathogen was created inside Kazakhstan’s government-run Research Institute for Biological Safety Problems, with technical collaboration from Seoul National University in South Korea, and funding provided by Kazakhstan’s Ministry of Education and Science.

According to the authors, they “generated recombinant influenza viruses expressing M. bovis antigens ESAT-6 and TB10.4 using a standard reverse genetic system.”

In plain terms, the team used reverse-genetics, a lab method that assembles new viruses from cloned DNA, to insert tuberculosis genes into the flu genome—creating a synthetic viral-bacterial hybrid.

They further explain: “We produced a vaccine strain expressing the M. bovis mycobacterial proteins ESAT-6 and TB10.4 from the NS1 open reading frame of the avian influenza virus through reverse genetics with virus replication in embryonated chicken eggs.”

In other words, the tuberculosis genes were physically embedded inside the influenza virus’s NS1 gene, then amplified inside live bird embryos to generate infectious viral particles.

The NS1 gene in bird flu controls the virus’s ability to evade the host immune system and replicate efficiently inside infected cells.

The generation of a bird flu-tuberculosis Franken-virus comes as the U.S. Department of Agriculture’s FY2026 emergency funding plan quietly placed both highly pathogenic avian influenza and bovine tuberculosis under the same permanent “no-year” emergency funding status—elevating bird flu and tuberculosis research, including gain-of-function and vaccine development, to federally protected, continuous-operation programs even during a full government shutdown.

Taken together, the creation of a live bird flu-tuberculosis chimera overseas and the U.S. government’s decision to grant both pathogens permanent emergency status raise serious national security concerns.

The timing and alignment of these actions suggest more than coincidence—raising pressing questions about whether global agencies and their partners are merely preparing for future outbreaks, or deliberately coordinating the groundwork for one.

Congress, the White House, the Department of Energy, the FBI, and the CIA have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

---

Insertion of ‘Alien Sequences’

The scientists note that the NS1 gene “was modified to include the antigen sequences.”

That means the flu virus’s genetic code was deliberately edited to carry foreign bacterial fragments.

They add: “The virus was attenuated by modifying the NS1 protein by inserting alien sequences derived from the target protein amino acid region 124.”

Translated, the researchers confirm they altered the flu virus by altering a key protein and inserting “alien” genetic material—a literal cross-species fusion between virus and bacterium.

Microscopic Confirmation of the Hybrid Virus

Under an electron microscope, “the virion morphology of the recombinant viruses corresponded to that of the avian influenza viruses. The virions were spherical and enclosed in a bilayer supercapsid with ~10 nm glycoprotein spikes, which determine the hemagglutinative or neuraminidase activity.”

Simply put, even after being spliced with tuberculosis genes, the new organism was said to still look and behave like an influenza virus—complete with its purported spike-covered shell used for cell infection.

Verified ‘Genetic Chimeric Structure’

Molecular testing showed the genetic combination held together across generations:
“The first cloning stage showed a preserved genetic chimeric structure in the NS1 genome segment, as confirmed by RT-PCR.*”

Meaning: laboratory sequencing confirmed the hybrid DNA remained intact, proving the chimeric virus was genetically stable and self-replicating.

The study’s schematic further details the exact makeup:

“The recombinant segment of the non-structural protein 1 (NS1) gene express[es] the ESAT-6 and TB10.4 antigens of the virulent 0078-Mycobacterium bovis-8/RIBSP strain. The yellow rectangle represents the NS1 regions, while the green rectangles represent the mycobacterial genes.”

In plain language, the figure shows flu genes (yellow) fused with tuberculosis genes (green)—a clear depiction of genetic grafting across species.

Replication & Stability

The team reported the new virus replicated efficiently:

“The recombinant vector expressing the mycobacterial antigens showed a high hemagglutination activity of 1:128 at an infectious activity level of lg 6.75 ± 0.07 EID50/0.2 mL.”

In other words, each dose contained roughly five million infectious particles, confirming robust viral growth.

They also verified the genetic insert stayed stable:

“To evaluate the stability of the inserted gene, five serial passages of the virus were carried out in embryonated chicken eggs at 34 °C.”

This means the hybrid virus could be re-grown repeatedly without losing its tuberculosis genes—evidence of lasting biological stability.

Bottom Line

The Veterinary World study confirms that scientists from Kazakhstan’s Research Institute for Biological Safety Problems and Seoul National University created a genetically engineered, self-replicating organism that merges the genetic material of tuberculosis bacteria with avian influenza virus.

Their own words describe a “recombinant influenza virus” with a “preserved genetic chimeric structure” and “alien sequences” inserted into the NS1 gene—a live, replicating influenza–tuberculosis chimera manufactured inside bird embryos.

The timing of this creation—coinciding with the U.S. government’s decision to grant both bird flu and bovine tuberculosis permanent emergency funding—raises profound national security questions.

It suggests a coordinated international framework in which the same pathogens now being engineered in foreign labs are simultaneously being prioritized and federally protected under U.S. biosecurity policy.

Whether framed as “vaccine research” or “preparedness,” these programs collectively point to a globally synchronized architecture of high-risk pathogen development and continuity planning—one that operates beyond public consent, outside normal oversight, and increasingly blurs the line between defense and deliberate design.

USDA Declares Bird Flu a Permanent Emergency, Ensures Funding Continuity Even During Government Shutdown

Avian influenza officially elevated above nearly every other disease in the country’s federal continuity plan—after USDA rolled out $1 billion bird flu plan earlier this year.

Secretary of Agriculture Brooke Rollins remarks announcing the MAHA (Make America Healthy Again) Commission, Thursday, May 22, 2025, in the East Room of the White House. (Official White House Photo by Joyce N. Boghosian)

The U.S. Department of Agriculture (USDA) has quietly confirmed that highly pathogenic avian influenza (H5N1)—the same “bird flu” virus currently at the center of international gain-of-function experiments and vaccine production—will continue to receive emergency funding even during a full government shutdown.

According to the USDA’s FY2026 Lapse of Funding Plan, issued last month, the agency’s Animal and Plant Health Inspection Service (APHIS) will keep drawing from so-called “no-year emergency funding balances” to sustain select animal and plant disease programs indefinitely.

Out of all diseases, bird flu made the list.

And unlike normal appropriations, no-year funds never expire.

“No-year emergency funding balances will support continuation of animal and plant health emergency programs including new world screwworm, highly pathogenic avian influenza, exotic fruit flies, African swine fever, bovine tuberculosis, and rabies,” the plan states on page 23.

The move comes after USDA Secretary Brooke Rollins in February rolled out a $1 billion plan for fighting bird flu.

While governments are creating both the problem and the solution for a future bird flu pandemic (as they did for COVID-19), the USDA is now ensuring that the funding pipeline for those very operations—viral manipulation, surveillance, and pharmaceutical development—remains permanently open, immune to congressional oversight, public objection, or even the collapse of the federal government itself.

USDA’s recent actions confirm that bird flu has been formally elevated to a standing national emergency—an institutionalized, self-perpetuating priority that guarantees the continuation of biosecurity and vaccine programs regardless of political process, fiscal restraint, or the existence of an actual outbreak.

The United Nations and the World Health Organization are also mobilizing their own pandemic command structure around bird flu—with the WHO reactivating its global influenza emergency framework and the U.N. convening 500 international “experts and decision-makers” for the world’s first-ever “Global Dialogue” on bird flu coordination—a synchronized effort that mirrors the pre-COVID buildup of global pandemic infrastructure.

---

A Stunning Admission: Bird Flu Funding Can’t Be Stopped

In plain terms, this funding admission means that even if Congress collapses, the White House freezes, and all other federal operations are shuttered—the U.S. government will still keep funding bird flu programs.

Not monkeypox, Ebola, Marburg, or Chikungunya—but bird flu.

That level of protection is extraordinary.

Bird flu has been singled out for continuous, uninterruptible funding, on par with national defense and nuclear security operations.

No other infectious disease—human or animal—is afforded this kind of permanent continuity status in the USDA’s emergency budget architecture.

This isn’t normal policy language.

It’s an institutional declaration that bird flu is being treated as a standing national emergency, whether or not an actual outbreak exists.

What does the government know that we don’t?

And why does the United States continue to perform dangerous gain-of-function experiments on bird flu viruses when Congress, the White House, the Department of Energy, the FBI, and the CIA have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation?

Why does NIAID Director Dr. Jeffery Taubenberger hold a patent on the carcinogenic BPL technology at the center of the Trump administration’s $500 million bird flu vaccine program if he’s simultaneously funding experiments that generate never-before-seen, hybrid “Frankenstein” bird flu pathogens?

Just before the COVID pandemic, former NIAID Director Anthony Fauci was funding similar dangerous coronavirus experiments while the government was simultaneously developing a COVID vaccine.

Taken together, these problem-solution orchestration patterns raise national security, conflict of interest, and informed consent concerns.

A Signal of Pre-Planned Pandemic Operations

This USDA no-year emergency bird flu funding revelation comes as federal and international partners are already pouring billions into bird flu vaccine stockpiling, cancer-linked bird flu jabs, and bird flu gain-of-function lab experiments.

The USDA’s emergency funding clause guarantees that none of these operations—research, surveillance, vaccine testing, or field trials—will ever be interrupted, even if the rest of the government runs out of money.

This continuity effectively locks in a permanent and unprecedented bird flu response infrastructure, insulating bird flu activities from public debate, budget oversight, or congressional defunding efforts.

In other words, the government has pre-authorized bird flu as the one disease that can bypass the normal political process.

Prioritizing Bird Flu Over All Else

The USDA’s plan lists only six diseases eligible for automatic emergency funding: H5N1 bird flu, African swine fever, rabies, bovine tuberculosis, exotic fruit flies, and New World screwworm.

Yet only one of these—H5N1—is currently the focus of global vaccine production, laboratory gain-of-function work, and pandemic-level preparedness programs.

This choice is not accidental.

It shows that H5N1 has been politically and financially elevated above all other animal diseases as the presumed next pandemic threat.

It also means federal agencies are ensuring that avian flu vaccine and biosecurity operations will proceed uninterrupted, regardless of whether Congress approves a budget or the public objects.

Implications: A Built-In Bird Flu Apparatus

The USDA’s FY2026 Lapse of Funding Plan document proves that the U.S. government has already built the infrastructure to respond to an H5N1 “emergency” long before any such emergency exists.

It guarantees:

• Constant funding for H5N1 surveillance, lab work, and vaccine production.
• Operational continuity across USDA, BARDA, and CEPI-linked vaccine programs.
• No congressional check or pause on H5N1-related activities—even under government collapse.

When paired with the ongoing gain-of-function experiments enhancing H5N1’s ability to infect mammals, this shows the federal government isn’t merely preparing for a bird flu outbreak—it’s institutionalizing it as a permanent national focus.

Bottom Line

The USDA’s FY2026 emergency funding plan quietly exposes how H5N1 bird flu has been hardwired into the U.S. government’s permanent emergency infrastructure.

While nearly every other program would go dark in a shutdown, bird flu remains protected—its funding guaranteed, its operations untouchable, its continuity automatic.

This is not routine budgeting.

It’s a declaration of institutional permanence for a virus that has not yet caused a human pandemic—an extraordinary move that places bird flu response programs on the same level as national defense and nuclear security.

By pre-authorizing H5N1 funding to flow indefinitely, the federal government has created a self-sustaining pandemic apparatus—one that cannot be defunded, debated, or democratically constrained.

Taken together, the USDA’s emergency funding clause, NIAID’s gain-of-function work, and the global vaccine push reveal a chilling reality: H5N1 isn’t just being prepared for—it’s being positioned.

The government has pre-selected bird flu as the next pandemic—and built a financial machine to keep that plan running forever.

Is the next bird flu pandemic no longer a question of if, but when?

WHO Quietly Reactivates Global Influenza Pandemic Apparatus for Bird Flu: ‘Journal of Infectious Diseases’

WHO received $8 billion during the COVID-19 pandemic—is that why it’s expanding bird flu pandemic response infrastructure instead of demanding bird flu gain-of-function be halted?

A Wednesday publication in the Journal of Infectious Diseases confirms the World Health Organization (WHO) is quietly expanding its global pandemic infrastructure—this time around the threat of an H5N1 “bird flu” pandemic.

Not chikungunya. Not Ebola. Not Nipah. Not monkeypox.

Bird flu: the very virus countries are dangerously enhancing in labs even as they develop the vaccines and drugs to contain it (see recommended reading below this article).

In other words, while governments are creating both the problem and the solution to a bird flu pandemic, the WHO is building the command structure that will manage the global response when that crisis arrives.

The WHO’s bird flu paper surfaces as the United Nations, the most consequential international institution in existence, convenes 500 experts for a “global dialogue” on the same threat, signaling that global institutions are quietly aligning their pandemic machinery around bird flu.

The new report was written by officials in the World Health Organization’s Department of Epidemic and Pandemic Management.

It describes a permanent coordination system linking governments, pharmaceutical companies, and humanitarian agencies through two mechanisms: the Pandemic Influenza Preparedness (PIP) Framework and a new Interim Medical Countermeasures Network (i-MCM-net).

Together, they allow WHO to “coordinate availability, equitable access to, and timely allocation of medical countermeasures at the global level: strengthen coordination efforts and provide strategic orientation to ensure a coherent response to pandemic threats, with a focus on the global level.”

Key Question: Why is the WHO more focused on creating bird flu pandemic response infrastructure than on demanding governments halt all gain-of-function and reverse genetics experiments on bird flu—or all pathogens, for that matter?

One reason might be that the World Health Organization received a total of approximately $8 billion in funding during the COVID-19 pandemic.

The massive inflow of cash was unprecedented in the organization’s history and timeframe, as it greatly exceeded the approved biennial program budget of $5.84 billion.

COVID-19 made the WHO richer than ever.

What would a bird flu pandemic bring in?

And is that potential pandemic profit more important to the WHO than stopping what causes pandemics in the first place?

Congress, the White House, the Department of Energy, the FBI, and the CIA have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

---

Built Around the Bird Flu Threat

WHO traces the origin of these systems to the early-2000s H5N1 outbreaks:

“During 2005, changes were observed in the epidemiology of H5N1 disease in animals, and human cases continued to occur with high mortality (33% to > 50% case fatality),” the new Journal of Infectious Diseases publication reads. “The virus evolved and expanded its geographical range and became endemic in poultry in parts of Asia, increasing the size of the population at risk.”

The paper explains that these events prompted creation of an international antiviral stockpile “for strategic use during an evolving outbreak.”

“Considering the impact of a pandemic caused by the highly pathogenic virus, WHO was asked to explore the establishment of an international stockpile of antivirals for strategic use during an evolving outbreak in an attempt to contain it at the source or at least delay spread.”

Two decades later, WHO again points to the potential of an H5N1 pandemic to justify maintaining that infrastructure indefinitely.

New Supply Agreements & Industry Partners

In May 2024 WHO signed a donation agreement with F. Hoffmann-La Roche Ltd., securing up to five million courses of Tamiflu over two years.

“These antiviral treatment courses would be critical in the early stages of the response to an influenza pandemic,” writes the WHO.

The supplement lists additional sponsors—Roche, Gilead, Shionogi, Cidara, Eradivir, Leyden Laboratories, and the International Federation of Pharmaceutical Manufacturers & Associations—showing direct corporate integration in the WHO’s antiviral and vaccine network.

How the Systems Intersect

WHO’s i-MCM-net is designed to manage global distribution of antivirals and vaccines once they are licensed or “emergency use” authorized.

(We do not need an Emergency Use Authorization (EUA) for any bird flu vaccines or pharmaceuticals because we already have safe and effective FDA-approved medicines for the disease: Xofluza and Ivermectin).

The international agency already tested the network by allocating 2.4 million monkeypox vaccine doses in 2024 and states it will serve as the operational model for future influenza events.

In effect, laboratory research, pharmaceutical development, and international logistics are now operating in parallel lanes that converge under WHO coordination whenever an influenza pandemic threat is declared.

The Scale of Coordination

The WHO paper also notes that the organization is activating the i-MCM-net before the forthcoming Pandemic Agreement enters into force:

“Pending entry into force of the WHO Pandemic Agreement, WHO is working with Member States and relevant partners to ensure the interim Medical Countermeasures Network (i-MCM net) is operational to respond to public health events requiring a coordinated international response.”

That means the infrastructure for global response is already functioning in anticipation of a coming H5N1 or other influenza emergency.

Bottom Line

Across science, industry, and policy, H5N1 bird flu has become the organizing focus of a worldwide pandemic-response regime.

While laboratories across the U.S., Europe, and Asia continue conducting gain-of-function and reverse-genetics experiments that enhance bird-flu viruses, governments and pharmaceutical companies are simultaneously developing the vaccines and antivirals to counter those same engineered strains.

At the center of it all, the World Health Organization is orchestrating the global command structure—the supply chains, stockpiles, and distribution systems that will deploy those medical products once the next pandemic is declared.

COVID-19 showed that pandemic response can generate unprecedented funding and influence for global health institutions.

The WHO’s current expansion suggests it is preparing to replicate that model—this time around H5N1.

Whether viewed as preparedness or unchecked consolidation of power, the coordination now underway is one of the most extensive and consequential mobilizations around a single virus threat since COVID-19—and it is happening in plain sight.

And no one’s talking about it.

But we are.

NIAID, DARPA, Bill Gates Intentionally Infect 80 Americans With Lab-Made Pandemic Influenza Virus: HHS Study

Majority of infected individuals became contagious to others, raising national security and informed consent concerns.

A federally run experiment funded by the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Advanced Research Projects Agency (DARPA), and the Bill & Melinda Gates Foundation deliberately infected 80 American adults with a lab-grown pandemic influenza virus at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.

Data from 74 of those infected were analyzed, and 53 of them (72% of analyzed participants, or at least 66% of all infected participants) were confirmed to be shedding the pathogen, meaning they were actively contagious and could infect others.

We do not know whether six participants who were excluded from the study after being deliberately infected were shedding the virus or not.

Regardless, 53 of the individuals became contagious to others.

The human-infection experiment—officially published in Science Translational Medicine (Aug. 2025) under the title “Nasal and systemic immune responses correlate with viral shedding after influenza challenge in people with complex preexisting immunity”—was conducted entirely under the jurisdiction of the U.S. Department of Health and Human Services (HHS).

The original HHS manuscript can be found here or downloaded below.

Nihms 2097372 (2)

2.1MB ∙ PDF file

Download

Lab-Made Pandemic Virus Used to Infect Humans

According to the paper, participants were “challenged with 10⁷ half-maximal tissue culture infectious dose (TCID₅₀) of a 2009 pandemic H1N1 strain, A/Bethesda/MM2/H1N1.”

That purported virus was not naturally circulating.

It was a lab-engineered clone of the 2009 pandemic influenza A (H1N1) virus, manufactured by NIH scientists in Bethesda and maintained as a standardized “human challenge” stock.

The virus name itself—A/Bethesda/MM2/H1N1—identifies it as an NIH-made strain.

The “Bethesda” designation marks its laboratory origin at NIH’s Maryland facility, and “MM2” denotes the second master-mix batch of the cloned challenge stock.

80 Individuals Deliberately Infected Under HHS Oversight

The study describes the deliberate exposure of 80 adults to this laboratory-made pandemic influenza strain in 2019.

“The challenge study (clinicaltrials.gov NCT01971255) was performed at the NIH Clinical Center between April and October 2019,” the study reads.

Interestingly, that means the 80 human participants were intentionally infected with the NIH-made H1N1 influenza virus roughly five to six months before COVID-19 was first reported in Wuhan, China (December 2019).

So, while the study was published in Science Translational Medicine in August 2025, the actual human infections occurred in mid-2019.

Half of those deliberately infected had been vaccinated roughly two months earlier with a commercial quadrivalent influenza vaccine; the other half had not.

“All 80 participants were brought into the NIH Clinical Center as mixed cohorts and challenged with 10⁷ TCID₅₀ of influenza A/Bethesda/MM2/H1N1 virus … and assessed daily for a minimum of 9 days.”

Although only 74 participants were ultimately included in the analysis (after six were excluded), every one of them was intentionally inoculated with a live, replication-competent pandemic virus.

The experiment was run on U.S. federal property by U.S. government scientists.

It was approved by the NIAID Institutional Review Board (IRB No. 19-I-0058), making it an officially sanctioned HHS human-infection study.

The human infection experiment was carried out under a multi-million U.S. taxpayer dollar project titled “Universal Influenza Vaccine Development” (project number 1ZIAAI001372), led by Dr. Jeffery Taubenberger.

Dr. Taubenberger—listed as an author on the study—is the current NIAID Director, taking over Anthony Fauci’s spot.

Taubenberger holds a patent for the carcinogenic BPL technology at the center of the Trump administration’s new ‘Generation Gold Standard’ influenza bird flu pandemic vaccine platform.

His agency is also directing U.S. tax dollars to fund the creation of never-before-seen “Frankenstein” bird flu viruses.

Confirmed 72% of Analyzed Participants—& at Least 66% of All Infected—Became Infectious

A total of 80 volunteers were deliberately infected with the NIH-made influenza virus, but data from only 74 participants were included in the final published analysis.

Among those 74 analyzed participants, 53 were confirmed to actively shed virus, meaning they were contagious.

Because the six excluded individuals were not evaluated for viral shedding, the true number of infectious participants could be higher, but only 53 are confirmed in the published dataset.

That equates to 72% of the analyzed group and at least 66% of everyone infected becoming contagious, some for several days.

Shedding was tracked by daily nasal swabs using the BioFire Respiratory Pathogen Panel and qRT-PCR testing for the influenza M gene.

Participants were considered “shedding” when viral RNA was detected in nasal-wash samples.

“[P]articipants shedding virus for two or more days showed higher early viral loads and exhibited stronger induction of antiviral responses compared with participants who shed virus for one day.”

The highest viral loads appeared in multiday shedders on days 1–3 post-infection, coinciding with the most severe flu-like symptoms, as measured by NIH’s FluPro symptom scoring system.

Vaccination Failed to Prevent Infection or Shedding

Vaccination did not prevent infection.

The paper admits that “vaccinated shedders” displayed increased T-cell activity and inflammatory markers, including CD8A, PD-L1, IFN-γ, IL-6, and TNF-β, compared to unvaccinated shedders—indicating that vaccination did not stop infection but instead triggered a hyper-inflammatory immune response.

Females were three times more likely to clear the infection after only one day of shedding, while males were more likely to shed virus for multiple days.

Funding: NIAID, DARPA, and Gates Foundation

The study lists its financial backers as:

• NIAID Intramural Research Program (grants AI000986-12 and AI001157-07)
• DARPA (Defense Advanced Research Projects Agency), contract HR0011831160
• Bill & Melinda Gates Foundation, grant OPP1178956

That combination of government and private funders represents the same triad—HHS, the Pentagon, and the Gates Foundation—responsible for many dual-use biological and “pandemic preparedness” programs that blur the line between public health and bio-defense research.

Containment & Biosafety Measures Not Disclosed

Remarkably, the 2025 Science Translational Medicine paper and HHS manuscript provide no description whatsoever of biosafety precautions—no mention of negative-pressure rooms, isolation conditions, or post-infection quarantine protocols to prevent secondary transmission.

Readers of the study are unable to verify how the government prevented infected subjects from spreading the lab-made virus to others, raising national security concerns.

It further raises grave informed-consent concerns, as individuals who interacted with these infected volunteers beyond the study setting were never informed that they might be exposed to an NIH-made pandemic influenza virus.

Given that 72 percent of participants were confirmed viral shedders, this omission raises serious biosafety and public-transmission concerns.

Conducted Entirely Under HHS Authority

The trial was hosted, funded, staffed, and overseen by HHS agencies from start to finish:

• Conducted at the NIH Clinical Center in Bethesda, Maryland
• Run by the NIAID Laboratory of Infectious Diseases
• Reviewed by an HHS Institutional Review Board
• Carried out under HHS Good Clinical Practice guidelines

In short, the U.S. Department of Health and Human Services infected 74 American adults with a lab-grown pandemic influenza virus to study viral shedding and immune-system responses—while omitting basic transparency about containment.

The nation’s top health agency is infecting Americans with pandemic-grade pathogens.

Bottom Line

The federally directed experiment—funded by NIAID, DARPA, and the Bill & Melinda Gates Foundation—was a live human-infection challenge using a lab-engineered influenza strain created by NIH scientists in Bethesda.

Eighty adults were deliberately infected with the laboratory-made pandemic H1N1 virus; data from 74 were analyzed, and 53 of them (72 % of those analyzed, or at least 66 % of everyone infected) were confirmed to be shedding the pathogen—actively contagious and capable of transmitting it to others.

The six excluded participants were also infected, but the government provided no data indicating whether they shed virus, leaving the full extent of contagiousness unknown.

No description was provided for biosafety controls, isolation conditions, or post-infection release criteria, meaning the public record offers no verification of how HHS prevented the spread of its own lab-created virus beyond the NIH facility.

This omission raises not only national-security concerns but also informed-consent violations, since people who may have interacted with participants outside the study were never notified of possible exposure to an NIH-made pathogen.

Although the paper frames the experiment as advancing “next-generation vaccine development,” its findings instead showed that vaccination failed to prevent infection or viral shedding and appeared to trigger immune hyperactivation in vaccinated participants.

The newly published HHS study therefore stands as a rare, fully documented example of the U.S. Department of Health and Human Services deliberately infecting American citizens with a laboratory-grown pandemic-grade virus—underwritten by HHS, DARPA, and the Gates Foundation, with no transparent account of how the resulting contagion was contained.

Enough is enough with this shit already.

U.K.-China Gain-of-Function Creates Airborne Bird Flu Viruses Capable of Infecting Humans and Other Mammals: ‘Journal of Virology’

National security in jeopardy as government-funded Chinese–U.K. team engineered bird flu viruses with a new mutation that let them infect human cells and spread through the air between mammals.

A September publication in the Journal of Virology confirms that Chinese and U.K. researchers have jointly created, enhanced, and tested new avian influenza “bird flu” viruses in the lab that acquired the ability to infect and spread among mammals through the air.

Congress, the White House, the Department of Energy, the FBI, and the CIA have confirmed that the COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation.

Such experimentation raises national security and biosafety concerns.

Countries all over the world are performing risky experiments on bird flu viruses while developing drugs for the disease, simultaneously creating both the problem and the solution, raising questions about conflicts of interest and motives.

The new study—led by Dr. Juan Pu and Dr. Jinhua Liu of China Agricultural University—used a plasmid-based reverse-genetics system to construct synthetic viruses based on H9N2, H7N9, and H3N8 avian-influenza backbones.

The team intentionally introduced a new mutation called PB2-E627V, a single amino acid change that does not occur naturally in these strains, which allows bird flu viruses to cross into humans.

“Recombinant viruses were generated using a plasmid-based reverse genetics system in the genetic background of 17/H9N2, 17/H7N9, and 22/H3N8,” the authors wrote.

---

What the Mutation Did

The PB2-627V mutation bridged the species barrier between birds and humans by allowing the virus to exploit host proteins in both.

“PB2-627V combines the viral properties of avian-like PB2-627E and human-like PB2-627K, facilitating AIVs to efficiently infect and replicate in chickens and mice by utilizing both avian- and human-origin ANP32A proteins.”

In other words, the modified viruses replicated like avian strains in birds and like human flu viruses in mammals—a dual-host adaptation that overcomes the natural molecular restriction that normally prevents bird flu from establishing infection in humans.

Aerosol Transmission in Mammals

Perhaps most disturbing, the researchers infected ferrets—the most widely accepted mammalian model for human influenza—and documented respiratory-droplet (aerosol) transmission.

“PB2-627V promotes efficient transmission between ferrets through respiratory droplets.”

This means the engineered H9N2 strain became airborne and contagious between mammals, an outcome that squarely fits the U.S. government’s definition of “enhanced Potential Pandemic Pathogen” (ePPP) research under the HHS P3CO framework, which covers any experiment that enhances the transmissibility or virulence of a pathogen so that it is likely capable of widespread and uncontrollable transmission in human populations.

Replication in Chickens, Mice, & Humans

The study showed that the lab-created viruses replicated efficiently in chicken lungs, increased viral loads in human-cell cultures, and caused more severe pathology in mice than wild-type strains.

The viruses were also serially passaged through five generations of live chickens, proving that PB2-627V remains genetically stable and transmissible in poultr.

This means the mutation could sustain itself in farm flocks and later spill over to people.

“PB2-627V showed a high potential for sustained prevalence in chickens,” the authors concluded.

Funded by Chinese & British Governments

The paper lists funding only from China and the United Kingdom:

“This work was funded by the National Key Research and Development Program of China (2021YFD1800202 and 2022YFF0802400 [J.P.] and 2024YFE0106000 [J.L.]), National Natural Science Foundation of China (32192450 [J.L.] and 32102661 [Z.J.]), and UK Biotechnology and Biological Sciences Research Council BBS/E/D/20002173 and UK Medical Research Council MR/Y015045/1”

Collaborating institutions included the Roslin Institute (University of Edinburgh), the University of Nottingham, and the University of Hong Kong, alongside China Agricultural University in Beijing.

In plain terms: the Chinese and British governments jointly funded and executed gain-of-function experiments that engineered avian flu viruses to infect mammals through the air.

Biosecurity & Ethical Concerns

The authors admit that contamination occurred in sequencing samples, though they claim those data were “excluded from the final results.”

“Due to potential contamination identified in sequencing samples from the second and third parallel experiments during subsequent analysis, all data from these experiments were excluded from the final results,” the study reads.

That means while performing next-generation sequencing (NGS) on viral samples, the researchers detected contamination in some of their experimental batches—specifically, in the second and third parallel experiments.

Such an admission in a study manipulating airborne bird flu viruses underlines serious biosafety questions about laboratory conditions and oversight.

There is no mention of independent biosecurity review, P3CO-style oversight, or international ethics board approval for the gain-of-function component of the work.

International Risk

The paper acknowledges that the PB2-627V mutation is already spreading naturally across multiple subtypes—including H5N1, H5N6, H7N9, H3N8, and H10N3—and has been found in humans, foxes, minks, tigers, and wild birds.

The authors warn:

“Given the global prominence of AIVs, it will be prudent to monitor influenza viruses for the PB2-627V mutation as a potential marker for zoonotic spread.”

That is an understatement.

What they have demonstrated is that lab-modified avian-flu viruses can now infect mammals and transmit through the air—a benchmark for pandemic-capable pathogens.

Bottom Line

The Journal of Virology paper by Guo et al. (2025) provides direct evidence that:

• China and the United Kingdom jointly conducted gain-of-function experiments on avian flu viruses.
• The resulting strains crossed the species barrier and became airborne between mammals.
• These experiments meet the U.S. government’s definition of enhanced Potential Pandemic Pathogen (ePPP) research.

In short: Western and Chinese scientists have again created lab-made bird-flu viruses capable of infecting mammals through the air—exactly the kind of experiment international biosecurity laws were supposed to prevent.

NIAID, DARPA, Bill Gates Intentionally Infect 80 Americans With Lab-Made Pandemic Influenza Virus: HHS Study

Majority of infected individuals became contagious to others, raising national security and informed consent concerns.

A federally run experiment funded by the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Advanced Research Projects Agency (DARPA), and the Bill & Melinda Gates Foundation deliberately infected 80 American adults with a lab-grown pandemic influenza virus at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland.

Data from 74 of those infected were analyzed, and 53 of them (72% of analyzed participants, or at least 66% of all infected participants) were confirmed to be shedding the pathogen, meaning they were actively contagious and could infect others.

We do not know whether six participants who were excluded from the study after being deliberately infected were shedding the virus or not.

Regardless, 53 of the individuals became contagious to others.

The human-infection experiment—officially published in Science Translational Medicine (Aug. 2025) under the title “Nasal and systemic immune responses correlate with viral shedding after influenza challenge in people with complex preexisting immunity”—was conducted entirely under the jurisdiction of the U.S. Department of Health and Human Services (HHS).

The original HHS manuscript can be found here or downloaded below.

---

Lab-Made Pandemic Virus Used to Infect Humans

According to the paper, participants were “challenged with 10⁷ half-maximal tissue culture infectious dose (TCID₅₀) of a 2009 pandemic H1N1 strain, A/Bethesda/MM2/H1N1.”

That purported virus was not naturally circulating.

It was a lab-engineered clone of the 2009 pandemic influenza A (H1N1) virus, manufactured by NIH scientists in Bethesda and maintained as a standardized “human challenge” stock.

The virus name itself—A/Bethesda/MM2/H1N1—identifies it as an NIH-made strain.

The “Bethesda” designation marks its laboratory origin at NIH’s Maryland facility, and “MM2” denotes the second master-mix batch of the cloned challenge stock.

80 Individuals Deliberately Infected Under HHS Oversight

The study describes the deliberate exposure of 80 adults to this laboratory-made pandemic influenza strain in 2019.

“The challenge study (clinicaltrials.gov NCT01971255) was performed at the NIH Clinical Center between April and October 2019,” the study reads.

Interestingly, that means the 80 human participants were intentionally infected with the NIH-made H1N1 influenza virus roughly five to six months before COVID-19 was first reported in Wuhan, China (December 2019).

So, while the study was published in Science Translational Medicine in August 2025, the actual human infections occurred in mid-2019.

Half of those deliberately infected had been vaccinated roughly two months earlier with a commercial quadrivalent influenza vaccine; the other half had not.

“All 80 participants were brought into the NIH Clinical Center as mixed cohorts and challenged with 10⁷ TCID₅₀ of influenza A/Bethesda/MM2/H1N1 virus … and assessed daily for a minimum of 9 days.”

Although only 74 participants were ultimately included in the analysis (after six were excluded), every one of them was intentionally inoculated with a live, replication-competent pandemic virus.

The experiment was run on U.S. federal property by U.S. government scientists.

It was approved by the NIAID Institutional Review Board (IRB No. 19-I-0058), making it an officially sanctioned HHS human-infection study.

The human infection experiment was carried out under a multi-million U.S. taxpayer dollar project titled “Universal Influenza Vaccine Development” (project number 1ZIAAI001372), led by Dr. Jeffery Taubenberger.

Dr. Taubenberger—listed as an author on the study—is the current NIAID Director, taking over Anthony Fauci’s spot.

Taubenberger holds a patent for the carcinogenic BPL technology at the center of the Trump administration’s new ‘Generation Gold Standard’ influenza bird flu pandemic vaccine platform.

His agency is also directing U.S. tax dollars to fund the creation of never-before-seen “Frankenstein” bird flu viruses.

Confirmed 72% of Analyzed Participants—& at Least 66% of All Infected—Became Infectious

A total of 80 volunteers were deliberately infected with the NIH-made influenza virus, but data from only 74 participants were included in the final published analysis.

Among those 74 analyzed participants, 53 were confirmed to actively shed virus, meaning they were contagious.

Because the six excluded individuals were not evaluated for viral shedding, the true number of infectious participants could be higher, but only 53 are confirmed in the published dataset.

That equates to 72% of the analyzed group and at least 66% of everyone infected becoming contagious, some for several days.

Shedding was tracked by daily nasal swabs using the BioFire Respiratory Pathogen Panel and qRT-PCR testing for the influenza M gene.

Participants were considered “shedding” when viral RNA was detected in nasal-wash samples.

“[P]articipants shedding virus for two or more days showed higher early viral loads and exhibited stronger induction of antiviral responses compared with participants who shed virus for one day.”

The highest viral loads appeared in multiday shedders on days 1–3 post-infection, coinciding with the most severe flu-like symptoms, as measured by NIH’s FluPro symptom scoring system.

Vaccination Failed to Prevent Infection or Shedding

Vaccination did not prevent infection.

The paper admits that “vaccinated shedders” displayed increased T-cell activity and inflammatory markers, including CD8A, PD-L1, IFN-γ, IL-6, and TNF-β, compared to unvaccinated shedders—indicating that vaccination did not stop infection but instead triggered a hyper-inflammatory immune response.

Females were three times more likely to clear the infection after only one day of shedding, while males were more likely to shed virus for multiple days.

Funding: NIAID, DARPA, and Gates Foundation

The study lists its financial backers as:

• NIAID Intramural Research Program (grants AI000986-12 and AI001157-07)
• DARPA (Defense Advanced Research Projects Agency), contract HR0011831160
• Bill & Melinda Gates Foundation, grant OPP1178956

That combination of government and private funders represents the same triad—HHS, the Pentagon, and the Gates Foundation—responsible for many dual-use biological and “pandemic preparedness” programs that blur the line between public health and bio-defense research.

Containment & Biosafety Measures Not Disclosed

Remarkably, the 2025 Science Translational Medicine paper and HHS manuscript provide no description whatsoever of biosafety precautions—no mention of negative-pressure rooms, isolation conditions, or post-infection quarantine protocols to prevent secondary transmission.

Readers of the study are unable to verify how the government prevented infected subjects from spreading the lab-made virus to others, raising national security concerns.

It further raises grave informed-consent concerns, as individuals who interacted with these infected volunteers beyond the study setting were never informed that they might be exposed to an NIH-made pandemic influenza virus.

Given that 72 percent of participants were confirmed viral shedders, this omission raises serious biosafety and public-transmission concerns.

Conducted Entirely Under HHS Authority

The trial was hosted, funded, staffed, and overseen by HHS agencies from start to finish:

• Conducted at the NIH Clinical Center in Bethesda, Maryland
• Run by the NIAID Laboratory of Infectious Diseases
• Reviewed by an HHS Institutional Review Board
• Carried out under HHS Good Clinical Practice guidelines

In short, the U.S. Department of Health and Human Services infected 74 American adults with a lab-grown pandemic influenza virus to study viral shedding and immune-system responses—while omitting basic transparency about containment.

The nation’s top health agency is infecting Americans with pandemic-grade pathogens.

Bottom Line

The federally directed experiment—funded by NIAID, DARPA, and the Bill & Melinda Gates Foundation—was a live human-infection challenge using a lab-engineered influenza strain created by NIH scientists in Bethesda.

Eighty adults were deliberately infected with the laboratory-made pandemic H1N1 virus; data from 74 were analyzed, and 53 of them (72 % of those analyzed, or at least 66 % of everyone infected) were confirmed to be shedding the pathogen—actively contagious and capable of transmitting it to others.

The six excluded participants were also infected, but the government provided no data indicating whether they shed virus, leaving the full extent of contagiousness unknown.

No description was provided for biosafety controls, isolation conditions, or post-infection release criteria, meaning the public record offers no verification of how HHS prevented the spread of its own lab-created virus beyond the NIH facility.

This omission raises not only national-security concerns but also informed-consent violations, since people who may have interacted with participants outside the study were never notified of possible exposure to an NIH-made pathogen.

Although the paper frames the experiment as advancing “next-generation vaccine development,” its findings instead showed that vaccination failed to prevent infection or viral shedding and appeared to trigger immune hyperactivation in vaccinated participants.

The newly published HHS study therefore stands as a rare, fully documented example of the U.S. Department of Health and Human Services deliberately infecting American citizens with a laboratory-grown pandemic-grade virus—underwritten by HHS, DARPA, and the Gates Foundation, with no transparent account of how the resulting contagion was contained.

NIAID Director Holds Patent for Bird Flu Pandemic Vaccine—as His Agency Creates Frankenstein Bird Flu Viruses in the Lab

Dr. Jeffery Taubenberger is creating the pandemic pathogen problem and the royalty-collecting vaccine solution at the same time—raising lab leak, national security, and conflict of interest concerns.

The U.S. National Institute of Allergy and Infectious Diseases (NIAID) is funding the laboratory creation of deadly, genetically engineered bird-flu viruses—even as its director, Dr. Jeffery Taubenberger, is named as an inventor on a U.S. government patent for a vaccine platform designed to counter those very pathogens.

In other words, the same federal agency making new bird-flu viruses is led by the man who helped invent—and could profit from—the vaccine meant to fight them.

Mainstream reports and federal documents confirm that Dr. Taubenberger could receive royalty payments if the vaccine platform proves successful.

Federal rules allow government inventors like Taubenberger to personally earn up to $150,000 a year in royalties from their patents.

This overlap between virus creation and vaccine ownership raises profound questions about conflicts of interest within America’s pandemic-preparedness system.

The same official overseeing the creation of potentially pandemic-causing bird-flu viruses also stands to earn personal income from the patented vaccine technology designed to combat them—a built-in conflict of interest at the very heart of U.S. pandemic research.

How secure is a nation whose top infectious-disease officials are simultaneously funding the creation of potential pandemic pathogens and positioned to profit from the vaccines meant to stop them?

---

Who Is Jeffery Taubenberger?

NIAID Director Dr. Jeffery Taubenberger gained fame for leading the team that sequenced and reconstructed the 1918 “Spanish flu” genome—the deadliest pandemic in modern history.

Dr. Taubenberger’s work on the Spanish flu virus involved the reconstruction and sequencing of one of the deadliest pandemics in history.

That project effectively resurrected an extinct virus under federal sponsorship, establishing Taubenberger as a pioneer of gain-of-function influenza research.

Bird flu belongs to the influenza family, meaning the very expertise Taubenberger developed by resurrecting the 1918 virus now underpins his agency’s funding of new, lab-engineered avian-influenza strains with similarly pandemic-capable properties.

Taubenberger replaced Anthony Fauci as acting NIAID director on April 25, 2025, following Fauci’s retirement in December 2022 and Jeanne Marrazzo’s tenure as director from 2023 until 2025.

Like Fauci before him, Taubenberger now presides over an agency channeling taxpayer dollars into the same kind of high-risk pathogen manipulation that helped set the stage for the COVID-19 disaster—continuing the very pattern of federally backed experimentation that muddles public health preparedness and pandemic provocation.

Bird Flu Takes Center Stage in Trump’s $500 Million ‘Generation Gold Standard’ Project

Under President Donald J. Trump, HHS and the NIH in May 2025 launched ‘Generation Gold Standard,’ a $500 million “next-generation, universal vaccine platform” centered on avian-influenza (“bird flu”) jab creation.

“These vaccines aim to provide broad-spectrum protection against multiple strains of pandemic-prone viruses like H5N1 avian influenza and coronaviruses including SARS-CoV-2, SARS-CoV-1, and MERS-CoV,” an HHS press release states.

The lead candidates—BPL-1357 and BPL-24910—use beta-propiolactone (BPL)-inactivated, whole-virus platforms.

Clinical trials are scheduled for 2026, with FDA review targeted for 2029.

The Patent & Potential Financial Stakes

Dr. Taubenberger is a named inventor on the BPL-inactivated bird-flu vaccine patent developed within NIH laboratories.

That means he holds a patent for the bird-flu vaccines at the center of Trump’s Generation Gold Standard program.

A May 2025 report in Science confirms that NIH “has two patents for the BPL-inactivated, universal flu vaccine,” that Taubenberger “is named as one of the inventors,” and that the NIAID director “stands to financially benefit from this project.”

The patent is confirmed in a Federal Register notice from December 2019.

The relevant patent application is titled “Broadly Protective Influenza Vaccine Comprising a Cocktail of Inactivated Avian Influenza Viruses.”

Put plainly, the federal official directing America’s bird-flu virus research is also positioned to earn personal royalties from the very vaccine platform his own agency is funding—tying Taubenberger’s financial interests directly to the emergence of a bird flu pandemic.

The Dual-Track Pattern Echoes of COVID-19

This dual track—create the pathogen, then sell the cure—echoes the pattern seen before COVID-19, when EcoHealth Alliance’s DEFUSE project proposed engineering chimeric coronavirus spikes and aerosolized self-spreading vaccines years before the 2019 outbreak.

A Frontiers in Virology study confirmed that Moderna’s 2016 patented spike-protein sequence—developed in partnership with DARPA years before the COVID-19 outbreak—matched the pandemic virus’s spike sequence with a one-in-three-trillion probability of occurring naturally.

Later, congressional investigators discovered that DARPA, the Department of Defense, and the Office of the Director of National Intelligence had classified and concealed EcoHealth Alliance’s DEFUSE proposal.

The plan outlined how to engineer SARS-like viruses with furin cleavage sites.

It prompted Senator Roger Marshall to warn that the cover-up may “rise to the level of misconduct, false statements, obstruction of federal proceedings, conspiracy, conflicts of interest, or infractions of administrative or civil laws.”

The parallels are striking: classified projects, overlapping incentives, and opaque oversight.

The New Bird-Flu Playbook

The COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation, according to Congress, the White House, the Department of Energy, the FBI, and the CIA.

Today, U.S. and international laboratories—funded by NIAID—are constructing new bird flu strains using reverse genetics and chimeric-virus methods.

• One recent NIAID-funded project produced a live hybrid H5N1 “Frankenstein” virus that infects human lung cells, resists flu medication, and mutates to evade vaccines.
• In another NIAID-backed project, researchers built entirely new bird-flu viruses with enhanced growth and replication traits.
• At the University of Pittsburgh, NIAID bankrolled experiments that created a never-before-seen chimeric bird-flu virus by fusing H5N1 genes onto a live vesicular stomatitis virus backbone.
• At Georgia State University, U.S. and South Korean researchers—backed by NIAID funding—recently created chimeric H5N1 bird-flu viruses by splicing genes from Asian outbreak strains onto a lab H1N1 backbone, producing synthetic hybrids that triggered severe inflammatory reactions in animal tests.
• At the University of Tokyo and the University of Wisconsin, NIAID-funded researchers led by Yoshihiro Kawaoka rebuilt a pandemic-capable H5N1 virus from synthetic gene clones, deliberately driving mammalian adaptation and drug resistance.
• In another recent NIAID-backed collaboration spanning the U.S., Japan, Egypt, and Austria, scientists used reverse genetics to stitch together wild H5N1 genes with a 1934 lab flu strain—creating a chimeric hybrid virus that proved 100% lethal in mammals.
• At the University of Missouri, NIAID-funded researchers engineered bat–human hybrid influenza viruses through reverse genetics that replicate efficiently in mammalian cells and resist common antivirals.
• In yet another recent NIAID-funded experiment, scientists engineered a multi-strain bird-flu virus in German labs using synthetic plasmids before shipping it to Alabama, where live ferret infection tests with H5N1 were performed under U.S. government direction.

The same tools central to the COVID-19 gain-of-function controversy are again in play.

The outcome is a closed loop: government-funded pathogen creation feeding government-funded vaccine development, overseen by officials with patent ties to the product side.

Bottom Line

Dr. Jeffery Taubenberger—the scientist who resurrected the 1918 flu—now directs NIAID, funds gain-of-function-style bird-flu research, and is a named inventor on the federally patented BPL vaccine platform at the heart of Trump’s $500 million Generation Gold Standard program.

According to Science and federal records, Taubenberger could personally earn royalties—up to $150,000 a year—from the same vaccine platform his own agency is financing, meaning the official funding bird-flu virus creation is also positioned to profit from the “solution.”

That built-in financial stake transforms what should be a public-health mission into a structural conflict of interest—one that blurs the line between national bio-defense and bio-commerce.

Once again, the U.S. government’s pandemic apparatus merges research, regulation, and remuneration—raising the question not of whether the next outbreak is being planned for, but whether it’s being prepared for profit.

NIH Funds Creation of New Frankenstein Bird Flu Virus in Europe—Tests It in Alabama: Journal ‘Vaccine’

Engineered in German labs using reverse genetics, then tested in U.S. animals with live H5N1 challenge.

A peer-reviewed study published this month in Vaccine details how the U.S. National Institutes of Health (NIH)—through its National Institute of Allergy and Infectious Diseases (NIAID)—funded and conducted live H5N1 “bird flu” experiments on ferrets using newly engineered chimeric influenza viruses that were synthetically constructed in Europe from the combined genetic material of multiple flu strains.

NIAID is led by Dr. Jeffery Taubenberger, widely recognized for leading the team that sequenced the 1918 influenza “Spanish flu” pandemic virus genome.

Dr. Taubenberger’s work on the Spanish flu virus involved the reconstruction and sequencing of one of the deadliest pandemics in history.

The revelation of new bird flu pathogen creation follows this website’s report that the NIH, led by Director Jayanta “Jay” Bhattacharya, and USDA have funded scientists to create other brand-new, never-before-seen avian influenza viruses with enhanced growth and replication traits at the University of Nebraska–Lincoln.

The Centers for Disease Control and Prevention (CDC) also recently engineered a brand-new strain of bird flu in its Atlanta, Georgia laboratories, signifying broad, multi-agency coordination of federally backed programs to genetically bioengineer new avian-influenza viruses across multiple institutions.

Moreover, the Department of Health and Human Services’ (HHS) Biomedical Advanced Research and Development Authority (BARDA) recently awarded Cidara $339 million for its new influenza drug CD388.

Each U.S. agency is contributing to a rapidly expanding network of synthetic bird-flu drug development and virus creation with heightened replication efficiency, immune-evasion features, and potential dual-use biosecurity risks.

---

Who Funded It

According to the acknowledgments:

“The ferret experiment was funded and carried out by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (USA) non-clinical and preclinical service programs through Southern Research Institute (USA) contract HHSN272201700029I/75N93020F00002 with Treamid Therapeutics GmbH (D.Pleimers).”

The work was supported by Treamid Therapeutics and UniFluVec.

That means the U.S. government financed part of the research, while two private European biotechnology firms oversaw the development of the new virus, signalling international bird flu pandemic orchestration.

The Southern Research Institute in Birmingham, Alabama carried out the ferret infection and live-virus challenge under NIH/NIAID direction.

“The experiment in ferrets was performed by National Institute of Allergy and Infectious Diseases (NIAID) National Institute of Health (USA) and Southern Research Institute (USA),” the study reads.

Where the Viruses Were Created

The paper confirms the engineered viruses were constructed in Europe:

“The recombinant influenza virus vector, UniFluVec, is based on the PR/8/34 influenza virus and constructed using the reverse genetics method with synthetic plasmids generated by GeneArt (Germany).”

That means synthetic plasmids were built by GeneArt, a Thermo Fisher Scientific division in Germany, then used by UniFluVec and Treamid Therapeutics to assemble a brand-new influenza virus before transferring materials for NIH-funded animal testing in the U.S.

What They Created

The new construct, called UniFluVec, is a hybrid influenza virus assembled from several different strains through reverse genetics, a process that reconstructs live viruses from cloned DNA:

“The recombinant influenza virus vector, UniFluVec… constructed using the reverse genetics method… The HA and NA fragments originate from A/Mississippi/10/2013 (H1N1pdm), while PB2, PB1, PA, NP, M and NS fragments—from PR/8/34 (H1N1).”

The authors then spliced in additional genetic material from multiple lineages:

“UniFluVec includes two key modifications in the NS segment: a truncated NS1 protein of 124 amino acids and a heterologous NEP protein from the A/Singapore/1/57-like (H2N2) virus. Additionally, the truncated NS1₁₂₄ protein was fused with a 21-amino-acids of the fusion peptide from the HA2 subunit of the B/Lee/1940 virus and a conserved nine-amino-acid B-cell epitope NP_243–251 of the PR/8/34 virus.”

This created a synthetic multi-strain hybrid virus containing genetic components from at least four different influenza species—H1N1, H1N1pdm, H2N2, and influenza B.

Testing with Live H5N1 Challenge

The synthetic UniFluVec virus was later tested against one of the world’s most lethal avian influenza strains:

“Vaccination of ferrets was performed within a biological safety cabinet (BSC). On study day 0, animals were anesthetized and vaccinated IN with 1.0 ml (0.5 ml/nares) of the PBS (vehicle control) or vaccine virus.”

“On day 21 or 23, each ferret was anesthetized and infected IN with 1.0 ml (approximately 0.5 ml/nares) of influenza virus A/Indonesia/5/2005 (H5N1).”

Bottom Line

The NIH-funded research demonstrates that synthetic, multi-strain chimeric influenza viruses were genetically constructed in Europe using reverse-engineered plasmids and then tested in live mammals with an H5N1 challenge in the United States.

Taken together with concurrent projects at the USDA, CDC, and BARDA, the work underscores a broad, multi-agency program to bioengineer, test, and commercialize novel avian-influenza viruses and related countermeasures—often under the banner of “vaccine” or “therapeutic” development.

While the authors describe their study as vaccine research, the combination of cross-continental virus construction, high-pathogenicity live-animal challenges, and U.S. federal coordination situates it squarely within the domain of gain-of-function–type experimentation, raising renewed questions about oversight, transparency, and biosecurity.

The COVID-19 pandemic was likely the result of lab-engineered pathogen manipulation, according to Congress, the White House, the Department of Energy, the FBI, and the CIA.